SCHEMBL5807459

SCHEMBL5807459

C=CCc1ccc(Cl)cc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 4/20 0.50
GABRB2 P47870 4/20 0.50
PTGDR Q13258 1/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.47
MAPT P10636 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
CYP3A4 P08684 2/20 0.45
HPGD P15428 2/20 0.45
HIF1A Q16665 2/20 0.45
SLC22A1 O15245 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSPD1 P10809 1/20 0.45
HSPA5 P11021 1/20 0.45
IDO1 P14902 1/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
CASP1 P29466 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490536 0.84 GABRA1 (0.66) GABRA1GABRB2PTGDRPTGDR2MAPT
SCHEMBL2318939 0.80 ERN1 (0.47) MAPTMEN1KMT2ACYP3A4HPGD
SCHEMBL249746 0.79 IDO1 (0.54) PTGDRPTGDR2MAPTCYP3A4HPGD
SCHEMBL30956678 0.79 IDO1 (0.54) PTGDRPTGDR2MAPTCYP3A4HPGD
SCHEMBL69697 0.79 TYR (0.58) GABRA1GABRB2MAPTMEN1KMT2A
Bromide SCHEMBL28225209 0.78 IDO1 (0.52) PTGDRPTGDR2MAPTCYP3A4HPGD
SCHEMBL1006107 0.78 XDH (0.70) GABRA1GABRB2MAPTMEN1KMT2A
SCHEMBL8259600 0.78 GABRA1 (0.52) GABRA1GABRB2MAPTMEN1KMT2A
SCHEMBL5024409 0.77 HPGD (0.42) MAPTMEN1KMT2ACYP3A4HPGD
SCHEMBL18551328 0.77 HSD17B10 (0.50) MAPTMEN1KMT2ACYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358716-B1 INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) MERCK SHARP & DOHME (US) 2016-01-06 EP disclosed
US-8815875-B2 Inhibitors of fatty acid binding protein (FABP) MERCK SHARP & DOHME CORP. (US) 2014-08-26 US disclosed
US-8815875-B2 Inhibitors of fatty acid binding protein (FABP) MERCK SHARP & DOHME CORP. (US) 2014-08-26 US disclosed
US-20110237575-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) MERCK SHARP & DOHME LLC 2011-09-29 US disclosed
US-20110237575-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) MERCK SHARP & DOHME LLC 2011-09-29 US disclosed
WO-2010056631-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) SCHERING CORPORATION (US) 2010-05-20 WO disclosed
WO-2006069096-A1 SILANOL DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS, INC. (US) 2006-06-29 WO disclosed
EP-0488381-B1 Polyhydroxyphenylene ether resin and process for preparing the same MITSUBISHI CHEM CORP (JP) 1997-01-29 EP disclosed
EP-0530442-B1 Process for producing a hydroxy-substituted poly (phenylene ether) resin MITSUBISHI CHEM CORP (JP) 1996-09-04 EP disclosed
EP-0513812-B1 Thermoplastic resin composition MITSUBISHI CHEM CORP (JP) 1996-03-27 EP disclosed
US-5266673-A Compatibilizer for polymer blends and alloys MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1993-11-30 US disclosed
US-5202409-A POLYHYDROXYPHENYLENE ETHER RESIN AND PROCESS FOR PREPARING THE SAME MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1993-04-13 US disclosed
EP-0530442-A1 Process for producing a hydroxy-substituted poly (phenylene ether) resin MITSUBISHI CHEMICAL CORPORATION (JP) 1993-03-10 EP disclosed
EP-0513812-A2 Thermoplastic resin composition MITSUBISHI CHEMICAL CORPORATION (JP) 1992-11-19 EP disclosed
US-5120800-A Boriding with borane compound having at least one boron-hydrogen bond and oxidizing MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1992-06-09 US disclosed
EP-0488381-A1 Polyhydroxyphenylene ether resin and process for preparing the same MITSUBISHI CHEMICAL CORPORATION (JP) 1992-06-03 EP disclosed
EP-0451819-A2 Process for preparing modified-polyphenylene ether MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1991-10-16 EP disclosed
US-4764521-A Leukotriene antagonists and a method of use there as ELI LILLY AND COMPANY (US) 1988-08-16 US disclosed
EP-0132367-B1 LEUKOTRIENE ANTAGONISTS ELI LILLY AND COMPANY (US) 1988-06-08 EP disclosed
EP-0132367-A2 Leukotriene antagonists ELI LILLY AND COMPANY (US) 1985-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237575-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) FABP4, FABP1, FABP3 GABRA1 1933/4885GABRB2 1196/4885PTGDR 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.